Skip to main content

Table 2 Incremental cost, effectiveness in terms of correct case detected and the incremental cost-effectiveness ratio

From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

Strategies Compared

Incremental cost

Incremental effectiveness

Sum of incremental effectiveness

ICER (cost/ true cases detected)

TP EGFR

TP ALK

TP ROS1

TN

1 vs 0

$ 1006.91

23.9%

2.4%

0.7%

41%

0.68

$ 1480.75

2 vs 1

$ 44.87

0.0%

0.03%

0.1%

4.5%

0.05

$ 961.46

3 vs 2

$ 822.59

3.1%

2.3%

0.7%

17.5%

0.24

$ 3479.11

  1. TP true positive, TN true negative, ICER Incremental Cost-Effectiveness Ratio. Note: 0 is equal to do no tests at all (not recommended)